Flexion Therapeutics (FLXN) Gets a Buy Rating from Needham
In a report released today, Serge Belanger from Needham maintained a Buy rating on Flexion Therapeutics (FLXN), with a price target of $20.00. The company’s shares closed last Wednesday at $12.97.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.2% and a 38.7% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Currently, the analyst consensus on Flexion Therapeutics is a Strong Buy with an average price target of $21.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.98 and a one-year low of $5.01. Currently, Flexion Therapeutics has an average volume of 534.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.